12-8861141-A-G
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2
The NM_144670.6(A2ML1):āc.3346A>Gā(p.Met1116Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000138 in 1,614,124 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_144670.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
A2ML1 | ENST00000299698.12 | c.3346A>G | p.Met1116Val | missense_variant | Exon 28 of 36 | 1 | NM_144670.6 | ENSP00000299698.7 | ||
A2ML1 | ENST00000541459.5 | c.1996A>G | p.Met666Val | missense_variant | Exon 17 of 25 | 2 | ENSP00000443174.1 | |||
A2ML1 | ENST00000539547.5 | c.1873A>G | p.Met625Val | missense_variant | Exon 17 of 25 | 2 | ENSP00000438292.1 | |||
ENSG00000282022 | ENST00000631830.1 | n.322-2865T>C | intron_variant | Intron 1 of 1 | 3 |
Frequencies
GnomAD3 genomes AF: 0.000440 AC: 67AN: 152138Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000192 AC: 48AN: 249414Hom.: 0 AF XY: 0.000185 AC XY: 25AN XY: 135292
GnomAD4 exome AF: 0.000107 AC: 156AN: 1461868Hom.: 1 Cov.: 31 AF XY: 0.000102 AC XY: 74AN XY: 727230
GnomAD4 genome AF: 0.000440 AC: 67AN: 152256Hom.: 0 Cov.: 32 AF XY: 0.000457 AC XY: 34AN XY: 74454
ClinVar
Submissions by phenotype
not specified Uncertain:1Benign:1
The c.3346A>G (p.M1116V) alteration is located in exon 28 (coding exon 28) of the A2ML1 gene. This alteration results from a A to G substitution at nucleotide position 3346, causing the methionine (M) at amino acid position 1116 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Variant summary: A2ML1 c.3346A>G (p.Met1116Val) results in a conservative amino acid change located in the Alpha-macroglobulin-like, TED domain (IPR011626) of the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00019 in 249414 control chromosomes, predominantly at a frequency of 0.0011 within the African or African-American subpopulation in the gnomAD database. The observed variant frequency within African or African-American control individuals in the gnomAD database is approximately 275 fold of the estimated maximal expected allele frequency for a pathogenic variant in A2ML1 causing Noonan Syndrome phenotype (4e-06), strongly suggesting that the variant is a benign polymorphism found primarily in populations of African or African-American origin. To our knowledge, no occurrence of c.3346A>G in individuals affected with Noonan Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. One ClinVar submitter (evaluation after 2014) cites the variant as likely benign. Based on the evidence outlined above, the variant was classified as likely benign. -
not provided Benign:2
- -
- -
A2ML1-related disorder Benign:1
This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at